PCRI's Alex and Dr. Scholz discuss Xofigo (radium-223), an injectible radioligand therapy used to treat extensive bone metastases when there are no visceral (organ) metastases and limited lymph node metastases.
0:06 How does Xofigo work? In what stage of prostate cancer is it used?
1:28 What is the patient experience of receiving treatment with Xofigo?
2:08 Should patients be taking any supplementary treatments with Xofigo?
2:59 Can Xofigo treat any type of metastatic lesion?
3:38 Does Xofigo affect PSA?
4:22 What is the response rate of Xofigo?
6:10 Based on the current standard of care, where does Xofigo fit into the current sequence of treatments?
7:13 Are there any negative drug interactions with Xofigo?
Don’t know your stage? Take the quiz: Visit [ Ссылка ]
To learn more about prostate cancer visit [ Ссылка ]
Who we are:
The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
The information on the Prostate Cancer Research Institute's YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs.
#ProstateCancer #Prostate #MarkScholzMD
